Results 221 to 230 of about 75,512 (260)
Some of the next articles are maybe not open access.
Immunophenotyping of Chronic Lymphocytic Leukemia
Clinical Laboratory, 2017Chronic Lymphocytic Leukemia (CLL) is one of the most common diagnoses made by flow cytometry laboratories. There is no consensus on which markers need to be used in flow cytometry for accurate immunophenotyping. Herein, we investigated the role of markers used in flow cytometry in the distinction between CLL and MCL.A total 339 recently diagnosed B ...
Falay, Mesude, Ozet, GÜLSÜM
openaire +3 more sources
Transplantation in chronic lymphocytic leukemia
Current Hematologic Malignancy Reports, 2007Although there have been no randomized trials comparing the outcome of stem cell transplantation (SCT) with standard chemotherapy for patients with chronic lymphocytic leukemia (CLL), increasingly, both autologous and allogeneic SCT approaches are being explored in this disease.
Rifca, Le Dieu, John G, Gribben
openaire +2 more sources
Chronic Lymphocytic Leukemia in the Dog
Journal of the American Veterinary Medical Association, 1980SUMMARY Lethargy and weight loss were associated with chronic lymphocytosis in a dog. The bone marrow was infiltrated with large numbers of small lymphocytes, similar to those appearing in blood. Clinical and laboratory examinations led to a diagnosis of chronic lymphocytic leukemia.
E M, Hodgkins, J G, Zinkl, B R, Madewell
openaire +2 more sources
Current Opinion in Hematology, 1997
Much progress has been made over the past year in our understanding of the cytogenesis, biology, and therapy of chronic lymphocytic leukemia (CLL). Further definition of common cytogenetic abnormalities in CLL make it appear that the identification of a new tumor suppressor gene is close at hand.
openaire +4 more sources
Much progress has been made over the past year in our understanding of the cytogenesis, biology, and therapy of chronic lymphocytic leukemia (CLL). Further definition of common cytogenetic abnormalities in CLL make it appear that the identification of a new tumor suppressor gene is close at hand.
openaire +4 more sources
Familial Chronic Lymphocytic Leukemia
Seminars in Oncology, 2006The role of inherited genetic factors in the etiology of chronic lymphocytic leukemia (CLL) and other B-cell lymphoproliferative disorders (LPDs) is now well established. Significant familial aggregation of CLL and B-cell LPDs has been demonstrated, but the mode of inheritance is unknown.
Gabrielle S, Sellick +2 more
openaire +2 more sources
Obinutuzumab for chronic lymphocytic leukemia
Expert Review of Hematology, 2014Chronic lymphocytic leukemia (CLL) is a frequent hematological malignancy that is incurable using standard approaches. Two anti-CD20 monoclonal antibodies (mAb), rituximab and ofatumumab, have been approved for CLL treatment. A new glycoengineered type II humanized anti-CD20 mAb, obinutuzumab (GA101), has been developed and demonstrates increased ...
Catherine, Rioufol, Gilles, Salles
openaire +2 more sources
Immunotherapy of chronic lymphocytic leukemia
Expert Review of Anticancer Therapy, 2001Chronic lymphocytic leukemia (CLL) is typically an indolent B-cell malignancy, primarily affecting the aging population. Standard cytotoxic treatment with alkylating agents or purine analogs is very effective at inducing remission. However, curative treatment is not yet available.
W G, Wierda, S, O'Brien
openaire +2 more sources
Management of Chronic Lymphocytic Leukemia
American Society of Clinical Oncology Educational Book, 2015Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) is usually diagnosed in asymptomatic patients with early-stage disease. The standard management approach is careful observation, irrespective of risk factors unless patients meet the International Workshop on CLL (IWCLL) criteria for “active disease,” which requires treatment.
Stephan, Stilgenbauer +2 more
openaire +2 more sources
Rituximab in chronic lymphocytic leukemia
Seminars in Oncology, 2003Chronic lymphocytic leukemia (CLL) is the most common adult leukemia but is currently incurable by conventional therapeutic interventions. Rituximab has proven efficacy and tolerability in non-Hodgkin's lymphoma, achieving response rates of 73% and 48% in previously untreated or relapsed/refractory indolent non-Hodgkin's lymphoma, respectively. However,
openaire +2 more sources
Treatment of Chronic Lymphocytic Leukemia
New England Journal of Medicine, 2020Chronic Lymphocytic Leukemia Treatment of CLL, the most common leukemia in the West, has undergone a revolution in the past few years with the development of agents that target signaling kinases an...
openaire +2 more sources